Autor: |
Kobak KA; Laboratory for the Applied Research on Cardiovascular System, Department of Heart Diseases, Wroclaw Medical University, Wrocław, Poland., Radwańska M; Laboratory for the Applied Research on Cardiovascular System, Department of Heart Diseases, Wroclaw Medical University, Wrocław, Poland., Dzięgała M; Laboratory for the Applied Research on Cardiovascular System, Department of Heart Diseases, Wroclaw Medical University, Wrocław, Poland., Kasztura M; Laboratory for the Applied Research on Cardiovascular System, Department of Heart Diseases, Wroclaw Medical University, Wrocław, Poland., Josiak K; Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.; Centre for Heart Diseases, Military Hospital, Wroclaw, Poland., Banasiak W; Centre for Heart Diseases, Military Hospital, Wroclaw, Poland., Ponikowski P; Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.; Centre for Heart Diseases, Military Hospital, Wroclaw, Poland., Jankowska EA; Laboratory for the Applied Research on Cardiovascular System, Department of Heart Diseases, Wroclaw Medical University, Wrocław, Poland. ewa.jankowska@umed.wroc.pl.; Centre for Heart Diseases, Military Hospital, Wroclaw, Poland. ewa.jankowska@umed.wroc.pl. |
Abstrakt: |
Iron deficiency (ID) is a common and ominous comorbidity in heart failure (HF) and predicts worse outcomes, independently of the presence of anaemia. Accumulated data from animal models of systemic ID suggest that ID is associated with several functional and structural abnormalities of the heart. However, the exact role of myocardial iron deficiency irrespective of systemic ID and/or anaemia has been elusive. Recently, several transgenic models of cardiac-specific ID have been developed to investigate the influence of ID on cardiac tissue. In this review, we discuss structural and functional cardiac consequences of ID in these models and summarize data from clinical studies. Moreover, the beneficial effects of intravenous iron supplementation are specified. |